Jacqueline Vo, MD
Rheumatology · Houston, TXNPI 1346338001
Payments from drug & device makers
Across 957 payments — averaging $543.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$386K
- Amgen$107K
- Pfizer$9K
- AbbVie$4K
- EMD Serono, Inc.$2K
- AstraZeneca$1K
- plus $11K from 36 others
Across 3 payments — averaging $182.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$548
What the payments were for
- Food & beverage$18,253100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 27 | $386,307 |
| Amgen(2 entities) | 102 | $106,514 |
| Pfizer | 71 | $8,570 |
| AbbVie | 215 | $4,499 |
| EMD Serono, Inc. | 4 | $2,328 |
| AstraZeneca(2 entities) | 60 | $1,443 |
| Argenx US, Inc. | 10 | $1,434 |
| Johnson & Johnson(3 entities) | 64 | $1,352 |
| UCB, Inc. | 61 | $1,317 |
| Novartis | 62 | $1,083 |
| GSK | 36 | $635 |
| Sanofi | 32 | $622 |
| Lilly USA, LLC | 31 | $565 |
| Radius Health, Inc. | 21 | $416 |
| E.r. Squibb & Sons, L.L.C. | 31 | $394 |
| Mallinckrodt Enterprises LLC | 14 | $317 |
| Mallinckrodt Hospital Products Inc. | 15 | $288 |
| ANI Pharmaceuticals, Inc. | 10 | $266 |
| Aurinia Pharma U.S., Inc. | 13 | $262 |
| Boehringer Ingelheim | 13 | $258 |
| Organon | 8 | $146 |
| Sobi, Inc | 5 | $134 |
| Cranial Technologies, Inc | 8 | $126 |
| Actelion Pharmaceuticals US, Inc. | 4 | $126 |
| Genentech USA, Inc. | 6 | $110 |
| Octapharma USA, Inc. | 2 | $97 |
| Merck | 6 | $87 |
| Ultragenyx Pharmaceutical Inc. | 3 | $64 |
| Invivyd Inc | 2 | $60 |
| Bristol Myers Squibb | 4 | $57 |
| Sandoz | 3 | $53 |
| Almatica Pharma LLC | 2 | $46 |
| Kyowa Kirin, Inc. | 2 | $41 |
| Medexus Pharma, Inc. | 2 | $29 |
| Bioventus LLC | 1 | $27 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $24 |
| Fresenius Kabi USA, LLC | 1 | $24 |
| Alvogen Inc | 1 | $18 |
| Celltrion USA Inc. | 1 | $17 |
| Gilead | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RAYOS$447
- Humira$239
- Tremfya$150
- VYVGART HYTRULO$135
- SAPHNELO$110
How this compares
$520,206 in reported general payments places this provider in the 90th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 81 | $823,557 |
| Humira PenAdalimumab | 73 | $639,272 |
| RinvoqUpadacitinib | 59 | $359,982 |
| Cimzia (2 Pack)Certolizumab Pegol | 55 | $339,727 |
| Simponi AriaGolimumab | 47 | $337,520 |
| OrenciaAbatacept/Maltose | 52 | $241,282 |
| RemicadeInfliximab | 38 | $224,447 |
| Enbrel MiniEtanercept | 27 | $216,159 |
| ActemraTocilizumab | 26 | $153,663 |
| Enbrel SureclickEtanercept | 21 | $151,508 |
| Cosentyx Sensoready PenSecukinumab | 13 | $112,883 |
| KevzaraSarilumab | 25 | $101,902 |
| ProliaDenosumab | 50 | $80,403 |
| Xeljanz XrTofacitinib Citrate | 13 | $73,363 |
| ForteoTeriparatide | 15 | $67,849 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSimponi Aria, Remicade | $1,352 | $561,96885 claims |
| AbbVieRinvoq | $4,499 | $359,98259 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,317 | $339,72755 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $394 | $241,28252 claims |
| AmgenProlia, Evenity (2 Syringes) | $106,514 | $130,84272 claims |
| SanofiKevzara | $622 | $101,90225 claims |
| Lilly USA, LLCForteo | $565 | $67,84915 claims |
| PfizerInflectra | $8,570 | $51,03112 claims |
| Radius Health, Inc.Tymlos | $416 | $36,83714 claims |
| OrganonRenflexis | $146 | $34,51613 claims |
| Medexus Pharma, Inc.Rasuvo | $29 | $9,15913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Houston
- Philip WallerHouston$4.9M
- Qaiser RehmanHouston$2.3M
- Michelle EisenbergHouston$1.8M
- Abigail NeimanHouston$1.7M
- Maureen MayesHouston$1.6M
- Wajeeha YousafHouston$1.3M
- Laila HassanHouston$870K
- Shervin AssassiHouston$667K
- Naureen AlimHouston$397K
- Paul PickrellAustin$40.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.